|Bid||0.00 x 3200|
|Ask||0.00 x 800|
|Day's Range||4.50 - 4.64|
|52 Week Range||3.20 - 6.15|
|Beta (3Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 21, 2019 - Jan 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.78|
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
President & CEO of Accuray Inc (NASDAQ:ARAY) Joshua Levine bought 25,000 shares of ARAY on 11/05/2018 at an average price of $4.75 a share.
Accuray (ARAY) delivered earnings and revenue surprises of -16.67% and 0.77%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Sunnyvale, California-based company said it had a loss of 11 cents. Losses, adjusted for asset impairment costs, were 7 cents per share. The radiation oncology company posted ...
SUNNYVALE, Calif. , Oct. 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2019 ended September 30, 2018 . Company Highlights ...
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The big shareholder groups in Accuray Incorporated (NASDAQ:ARAY) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions Read More...
SUNNYVALE, Calif. , Oct. 17, 2018 /PRNewswire/ -- Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated ...
SUNNYVALE, Calif. , Oct. 11, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2018 on Tuesday, October 30, 2018 after the market close. ...
SUNNYVALE, Calif., Oct. 9, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Klinikum rechts der Isar der Technischen Universität München (TUM) clinical team has treated the first cancer patients in Germany with the innovative Radixact® System. This next-generation helical radiation therapy technology replaced an existing, earlier generation TomoTherapy® System at TUM, reinforcing its value to the hospital as a workhorse radiation therapy device capable of treating a wide range of indications from simple to complex.
SUNNYVALE, Calif., Oct. 4, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the clinical team at Healthcare Global Enterprises (HCG) EKO, Kolkata, has treated the first patient in India using the Radixact® System. HCG EKO is part of Healthcare Global Enterprises Ltd HCG, India's largest provider of cancer care.
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...
SUNNYVALE, Calif., Sept. 25, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that published data from two prospective, multi-center studies using differing protocols provide consistent results and reinforce the use of the CyberKnife® System for the effective management of low- and intermediate-risk prostate cancer. The studies were recently published online in the International Journal of Radiation Oncology*Biology*Physics and in the European Urology Oncology. The CyberKnife System delivers radiation with sub-millimeter precision, enhancing clinicians' ability to treat effectively while preserving healthy tissue.
How far off is Accuray Incorporated (NASDAQ:ARAY) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Scientific ...
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Warning! GuruFocus has detected 1 Warning Sign with ARAY. For the last quarter Accuray Inc reported a revenue of $113.8 million, compared with the revenue of $112.1 million during the same period a year ago.
In August, nine analysts are covering Varian Medical Systems (VAR) stock. Three of them have given the stock a “strong buy” rating, three have given it a “hold,” and three have given it a “sell.” The mean rating for VAR stock is 2.67 with a target price of $122. That implies an upside potential of 9.1% over its closing price of $111.83 on August 20.